ifetroban
Small moleculeexperimental
Ifetroban is a potent and selective thromboxane receptor antagonist. It has been studied in animal models for the treatment of cancer metastasis, myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy, and for its effects on platelets. Clinical trials are evaluating the therapeutic safety and efficacy of oral ifetroban capsules for the treatment of cancer metastasis, cardiovascular disease, aspirin exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. — Wikipedia
Clinical trial activity
10 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2011 (NCT01436500)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
- Asthma · Phase 2
- Asthma, Aspirin-Induced · Phase 2
- Autoimmune Diseases · Phase 2
- Cardiomyopathy, Dilated · Phase 2
- Cardiovascular Diseases · Phase 2
- Connective Tissue Diseases · Phase 2
- Hepatorenal Syndrome · Phase 2
- Hypertension, Portal · Phase 2
- Idiopathic Pulmonary Fibrosis · Phase 2
- Liver Cirrhosis · Phase 2
- Lung Diseases · Phase 2
- Muscular Dystrophy, Duchenne · Phase 2
- Nasal Polyps · Phase 2
- Neoplasms · Phase 2
- Pathologic Processes · Phase 2
- Scleroderma, Diffuse · Phase 2
- Scleroderma, Limited · Phase 2
- Scleroderma, Systemic · Phase 2
- Skin Diseases · Phase 2
- Vascular Diseases · Phase 2
Mechanism of action
- Thromboxane A2 receptorINHIBITOR
TBXA2R inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCNC(=O)c1coc([C@H]2[C@@H](Cc3ccccc3CCC(=O)O)[C@@H]3CC[C@H]2O3)n1- Mol. weight
- 440.54 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIfetroban ↗
- ChEMBLCHEMBL3301674 ↗
- ChEMBLCHEMBL3301673 ↗
Also known as
- benzenepropanoic acid, 2-((3-(4-((pentylamino)carbonyl)-2-oxazolyl)-7-oxabicyclo(2.2.1)hept-2-yl)methyl)-, (1s-(exo,exo))-
- bms180291
- bms 180291
- bms-180291
- bms-180291
- bms-180291
- ifetroban
- ifetroban
- ifetroban
- ifetroban
- ifetroban
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05571059 | Phase 2 | Mar 31, 2023 | Cumberland Pharmaceuticals |
| NCT03962855 | Phase 2 | Jul 31, 2019 | American Heart Association, Cumberland Pharmaceuticals, University of Massachusetts |
| NCT03694249 | Phase 2 | Dec 12, 2018 | Cumberland Pharmaceuticals, Vanderbilt University |
| NCT03340675 | Phase 2 | Nov 30, 2018 | Cumberland Pharmaceuticals, Vanderbilt University |
| NCT03326063 | Phase 2 | Apr 26, 2018 | Harvard University |
| NCT03028350 | Phase 2 | Jun 30, 2017 | Cumberland Pharmaceuticals, Scripps |
| NCT02802228 | Phase 2 | Mar 6, 2017 | Cumberland Pharmaceuticals, Medical University of South Carolina |
| NCT02682511 | Phase 2 | Jan 1, 2017 | Cumberland Pharmaceuticals, Vanderbilt University |
| NCT02216357 | Phase 2 | Aug 1, 2014 | Cumberland Pharmaceuticals |
| NCT01436500 | Phase 2 | Oct 1, 2011 | Cumberland Pharmaceuticals, University of Alabama, Birmingham |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cumberland Pharmaceuticals | For profit | 9 | 7 | 1 | 2011 |
| Vanderbilt University | Academic/Hospital | 3 | 1 | 1 | 2017 |
| American Heart Association | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Medical University of South Carolina | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Scripps | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Massachusetts | Academic/Hospital | 1 | 1 | 1 | 2019 |
8 organizations
Page 1 / 1